Other relevant alterations include defective Notch, PI3K, RAS-MEK and forkhead box protein M1 (FOXM1) signaling pathways, as well as mutations in TP53, MTOR or MYC in high-grade serous or endometrioid OCs, mutations in ARID1A, PIK3CA and PTEN in clear-cell carcinomas, and KRAS, BRAF or CDKN2A mutations in mucinous carcinomas [2]. This evidence concerns the gene FOXM1 and mucinous adenocarcinoma.